5,6-bis-(4-methoxy-phenyl)-[1,2,4]triazin-3-ylamine | 10243-77-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5,6-bis-(4-methoxy-phenyl)-[1,2,4]triazin-3-ylamine
• 英文别名: 3-amino-5,6-bis(4-methoxyphenyl)-1,2,4-triazine；5,6-bis(4-methoxyphenyl)-1,2,4-triazin-3-amine
• CAS: 10243-77-3
• 化学式: C₁₇H₁₆N₄O₂
• 分子量: 308.34
• InChiKey: WRIJZPOJLAFHTF-UHFFFAOYSA-N

物化性质

• 沸点：
  521.0±60.0 °C(Predicted)
• 密度：
  1.233±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  83.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  庚醛 、 5,6-bis-(4-methoxy-phenyl)-[1,2,4]triazin-3-ylamine 以 溶剂黄146 为溶剂， 反应 1.5h， 生成 [5,6-bis(4-methoxyphenyl)-[1,2,4]-triazin-3-yl]heptylidine-amine
  参考文献：
  名称：

  Monomer 5, 6-Diphenyl-1.2.4-Traizinic Derivatives and the Use Thereof

  摘要：

  该发明涉及使用通式(I)的5,6-二苯基-1,2,4-三唑化合物，其中环穿透键显示一个邻位、间位或对位的不同取代位置，相同或不同的R1和R2代表氢、氟、氯或溴原子，C1至C12直链或支链烷基，C1至C18直链或支链羟基、烷氧基聚（乙氧基）-烷氧基，具有从1到4的乙氧基数的C1至C4烷基片段和氨基或单或双烷基氨基，具有C1至C4烷基片段的羟基、氨基、苯基，可能被羟基取代1到3次，位于对位或苯基位置，可能被C1至C12烷氧基或氰基或烷基氨基团取代1到3次，形式为活性防晒剂或光保护剂的化妆品组合物中含有所述化合物。

  公开号：

  US20080299055A1
• 作为产物：
  描述：

  4,4'-二甲氧基苯酚酯 、 氨基胍媒染剂 以 乙醇 为溶剂， 反应 12.0h， 以65%的产率得到5,6-bis-(4-methoxy-phenyl)-[1,2,4]triazin-3-ylamine
  参考文献：
  名称：

  Monomer 5, 6-Diphenyl-1.2.4-Traizinic Derivatives and the Use Thereof

  摘要：

  该发明涉及使用通式(I)的5,6-二苯基-1,2,4-三唑化合物，其中环穿透键显示一个邻位、间位或对位的不同取代位置，相同或不同的R1和R2代表氢、氟、氯或溴原子，C1至C12直链或支链烷基，C1至C18直链或支链羟基、烷氧基聚（乙氧基）-烷氧基，具有从1到4的乙氧基数的C1至C4烷基片段和氨基或单或双烷基氨基，具有C1至C4烷基片段的羟基、氨基、苯基，可能被羟基取代1到3次，位于对位或苯基位置，可能被C1至C12烷氧基或氰基或烷基氨基团取代1到3次，形式为活性防晒剂或光保护剂的化妆品组合物中含有所述化合物。

  公开号：

  US20080299055A1

文献信息

• [EN] CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS<br/>[FR] BLOQUEUR DE CANAUX SODIQUES TRIAZOÏQUES ET DIAZOÏQUES CYCLIQUES
  申请人：UNIV GREENWICH

  公开号：WO2009090431A1

  公开（公告）日：2009-07-23

  Compounds of general structure in which X and Y are each N or C with at least one of X and Y being N; Z is a single bond or an optionally substituted linking group R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when RI is hydrogen or =NH when R1 is a substituent group; or N* is a group NRaRb where Ra and Rb are independently H or an alkyl group; or N* is an optionally substituted piperazinyl ring; and A is an optionally substituted heterocyclic or carbocyclic ring system which may be linked to the triazo/diazo ring through R2 to form a fused multicyclic ring; are indicated as suitable for treatment of disorders in mammals that are susceptible to sodium channel blockers and antifolates, and particularly disorders such epilepsy, multiple sclerosis, glaucoma and uevitis, cerebral traumas and cerebral ischaemias, stroke, head injury, spinal cord injury, surgical trauma, neurodegenerative disorders, motorneurone disease, Alzheimer's disease, Parkinson's disease, chronic inflammatory pain, neuropathic pain, migraine, bipolar disorder, mood, anxiety and cognitive disorders, schizophrenia and trigeminal autonomic cephalalgias; for treatment of mammalian cancers; and for treatment of malaria.

  通用结构化合物，其中X和Y分别为N或C，至少X和Y中的一个为N；Z是单键或可选择性取代的连接基团；R1是氢或取代基团；R2是氨基或取代基团；N*是氨基，当R1为氢或=NH时，当R1为取代基团时；或N*是一个NRaRb基团，其中Ra和Rb分别为H或烷基基团；或N*是一个可选择性取代的哌嗪环；A是一个可选择性取代的杂环或碳环系统，可以通过R2与三唑/重氮环连接形成融合的多环环；适用于治疗对钠通道阻滞剂和抗叶酸类药物敏感的哺乳动物的疾病，特别是癫痫、多发性硬化、青光眼和葡萄膜炎、脑外伤和脑缺血、中风、头部损伤、脊髓损伤、手术创伤、神经退行性疾病、运动神经元疾病、阿尔茨海默病、帕金森病、慢性炎症性疼痛、神经病性疼痛、偏头痛、双相情感障碍、情绪、焦虑和认知障碍、精神分裂症和三叉神经自主性头痛；用于治疗哺乳动物癌症；以及用于治疗疟疾。
• [EN] 1,2,4-TRIAZINE-4-AMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,2,4-TRIAZINE-4-AMINE
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2011095625A1

  公开（公告）日：2011-08-11

  According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1- A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.

  根据该发明提供了一种A1式化合物，可能对通过抑制A1-A2b或特别是A2a受体而得到改善的疾病或紊乱治疗有用，其中A1式化合物具有以下结构，其中，A代表Cy1或HetA；Cy1代表一个由一个、两个或三个环组成的5-至14-成员芳香、完全饱和或部分不饱和的碳环系统，该Cy1基团可选择地被一个或多个R4a取代基所取代；HetA代表一个由一个、两个或三个环组成的5-至14-成员杂环基团，可能是芳香、完全饱和或部分不饱和的，并且含有从O、S和N中选择的一个或多个杂原子，该杂环基团可能包括一个、两个或三个环，且该HetA基团可选择地被一个或多个R4b取代基所取代；B代表Cy2或HetB；Cy2代表一个由一个或两个环组成的3-至10-成员芳香、完全饱和或部分不饱和的碳环系统，该Cy2基团可选择地被一个或多个R4c取代基所取代；HetB代表一个由一个或两个环组成的3-至10-成员杂环基团，可能是芳香、完全饱和或部分不饱和的，并且含有从O、S和N中选择的一个或多个杂原子，该杂环基团可能包括一个或两个环，且该HetB基团可选择地被一个或多个R4d取代基所取代。
• Monomer 5, 6-diphenyl-1.2.4-traizinic derivatives and the use thereof
  申请人：Pierre Fabre Dermo-Cosmetique

  公开号：US08053573B2

  公开（公告）日：2011-11-08

  The invention relates to the use of 5,6-diphenyl-1,2,4-triazinic compounds of general formula (I), wherein cycle penetrating bonds display an ortho, meta or para indifferent substitution position, identical or different R1 and R2 represent a hydrogen, fluoride, chloride or bromine atom, C1 to C12 linear or branched alkyl, C1 A C18 linear or branched hydroxy, alkoxy poly(ethoxy)-alkoxy with a C1 to C4 alkyl fragment and an ethoxy number ranging from 1 to 4, amino or mono or di-alkylamino with a C1 to C4 alkyl fragment group, R3 represents a chlorine atom, a hydroxy, amino, a phenyl possibly 1 to 3 times substituted by a hydroxy radical situated at least in a para or phenyl position possibly 1 to 3 times substituted in an ortho, meta or para position by a C1 to C12 alkoxy or cyano or alkymino group with a C1 to C7 alkyl fragment in the form of active sun filters or light-protective agents and to cosmetic composition containing said compounds.

  本发明涉及使用通式（I）的5,6-二苯基-1,2,4-三氮唑化合物，其中环穿透键显示为正交、间位或对位的不同取代位置，相同或不同的R1和R2表示氢、氟、氯或溴原子、C1至C12的线性或支链烷基、C1至C18的线性或支链羟基、烷氧基、聚（乙氧基）-烷氧基，其具有C1至C4的烷基片段和乙氧基数在1至4之间，氨基或单或双烷基氨基，其具有C1至C4的烷基片段，R3表示氯原子、羟基、氨基、苯基，可能在对位或苯基位置上至少有1至3次取代的羟基基团，或在正交、间位或对位上至少有1至3次取代的C1至C12烷氧基、氰基或烷基氨基基团，以活性防晒剂或光保护剂的形式和含有该化合物的化妆品组合物。
• 1,2,4-TRIAZINE-4-AMINE DERIVATIVES
  申请人：Congreve Miles Stuart

  公开号：US20130029963A1

  公开（公告）日：2013-01-31

  According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A 1 -A 2b or, particularly, the A 2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy 1 or Het A ; Cy 1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy 1 group is optionally substituted by one or more R 4a substituents; Het A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy 2 or Het B ; Cy 2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy 2 group is optionally substituted by one or more R 4c substituents; Het B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het B group is optionally substituted by one or more R 4d substituents.

  根据本发明提供了一种A1式化合物，该化合物可能有用于治疗通过抑制A1-A2bor，特别是A2a受体而改善的疾病或疾病状态，其中A1式化合物具有以下结构，其中A代表Cy1或HetA；Cy1代表一个5到14个成员的芳香族、完全饱和或部分不饱和的碳环状环系，包括一个、两个或三个环，该Cy1基团可以被一个或多个R4a取代；HetA代表一个5到14个成员的杂环基团，可能是芳香族、完全饱和或部分不饱和的，并且其中包含一个或多个从O、S和N中选择的杂原子，该杂环基团可以包括一个、两个或三个环，该HetA基团可以被一个或多个R4b取代；B代表Cy2或HetB；Cy2代表一个3到10个成员的芳香族、完全饱和或部分不饱和的碳环状环系，包括一个或两个环，该Cy2基团可以被一个或多个R4c取代；HetB代表一个3到10个成员的杂环基团，可能是芳香族、完全饱和或部分不饱和的，并且其中包含一个或多个从O、S和N中选择的杂原子，该杂环基团可以包括一个或两个环，该HetB基团可以被一个或多个R4d取代。
• CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS
  申请人：University of Greenwich

  公开号：US20140155403A1

  公开（公告）日：2014-06-05

  A method of treating a disorder. The method includes administering to a subject in need thereof a compound of formula (I): Each of A, N*, X, Y, Z, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.

  一种治疗疾病的方法。该方法包括向需要治疗的受试者施用式（I）的化合物：其中A、N*、X、Y、Z、R1和R2均在此定义。还公开了该式的化合物和包含该化合物的制药组合物。